Approach

Summary

Licensing status

Publication and contact information

Assays & screens

Four-gene recombination proficiency score to guide the use of DNA-damaging cancer therapies

Studies in patient tumor samples have identified a four-gene expression signature that could help determine prognosis and guide treatment for various cancers. The signature quantifies the efficiency of DNA repair pathways and is based on the mRNA levels of four DNA repair-associated genes-RAP1 interacting factor homolog (RIF1), X-ray repair complementing defective repair in Chinese hamster cells 5 (XRCC5; KU80), PARP1 binding protein (PARPBP; PARI) and RAD51 homolog (RAD51). In tumors from patients with non-small cell lung cancer (NSCLC) treated with surgery plus DNA-damaging, platinum-based chemotherapy, a low signature score was associated with increased patient survival. Next steps include further characterizing the molecular responses associated with downregulation of the four genes.

SciBX 7(16); doi:10.1038/scibx.2014.471
Published online April 24, 2014

Provisional patent application filed; available for licensing

Pitroda, S.P. et al. Sci. Transl. Med.; published online March 26, 2014;
doi:10.1126/scitranslmed.3008291
Contact: Phillip P. Connell, The University of Chicago, Chicago, Ill.
e-mail:

pconnell@radonc.uchicago.edu